All In Biotech

Drug Trial Radar · NCT04155918

Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients

A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of AR882 Administered Alone or in Combination With Febuxostat or Allopurinol in Gout Patients

Last checked: Nov 19, 2026Latest source record: Nov 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Feb 3, 2020

Primary completion

Sep 3, 2020

Study completion Sep 3, 2020

Sponsor

Lead sponsor
Arthrosi TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 7, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed to evaluate the PK/PD, safety and tolerability of AR882 alone or in combination with febuxostat or allopurinol when administered to gout patients.

Conditions

  • Gout Patients

Interventions

  • Group 1: AR882 Alone and in Combination with Febuxostat (FBX)Drug

    AR882 + Febuxostat, AR882 alone, Febuxostat alone

  • Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)Drug

    AR882 + Allopurinol, AR882 alone, Allopurinol alone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PD profile of AR882 administered alone or in combination with febuxostatTime frame: 22 Days
  2. PD profile of AR882 administered alone or in combination with allopurinolTime frame: 22 Days
  3. Serum uric acid (sUA) response rateTime frame: 22 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Christchurch Clinical Studies Trust, Ltd (CCST)

    Christchurch, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.